Solara Active Pharma Sciences Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/r0131e2gl376hilfrmo7fh4g.pdf

Key Takeaways


Revenue & Margin Trajectory

Jitesh Devendra: "With a focus on all the actions above, we are confident that in outgoing Q4, we will return to our historical revenue, run rate of minimum Rs.400 crores per quarter with mid-teens EBITDA margin and turning PAT positive."

Vizag Facility: Approvals, Timelines & Utilization


Ibuprofen & Base Business Dynamics

Jitesh Devendra: "Pricing is pretty stable on ibuprofen and on other key APIs also what we manufacture and the inventory level of ibuprofen for us as I said, in the first half, also we had seen a decent demand. I would not say a great one. This is what we are expecting in the second half and the inventory levels are not a concern at all."

CRAMS: Building a Second Leg

Jitesh Devendra: "No, we want CRAMS to be definitely a bigger piece than being a single digit... we want to grow this business and not just maintain it at 5%."

Regulatory & Filing Pipeline


Guidance & Commitments

CommitmentSpecificsTimeline
Quarterly revenue run rateReturn to minimum Rs.400 crores per quarterQ4 FY2023 (possibly Q3)
EBITDA marginMid-teens EBITDA marginQ4 FY2023
PATTurn PAT positiveQ4 FY2023
Gross marginExit at 50% gross marginQ4 FY2023
Vizag under-recoveryUnder-recoveries to be met / neutralizedQ4 FY2023
Vizag US FDA inspectionPrior-approval inspection (PAI) expectedH2 FY2024
Vizag full capacity utilizationFull-fledged operations at capacityEnd of FY2024
Net debt-to-EBITDANormalized position of 2.5x to 3xFY2024
CRAMS material revenueTraction from US effortsFY2024
Ibuprofen China commercial suppliesCommercial supplies begin2024
CRAMS sizable portionBecome a sizable portion of the business3-to-4-year horizon
Brazil product filingsFile three to four productsCurrent financial year (FY2023)
New product filings (R&D)File six new productsCurrent financial year (FY2023)
Vizag new product filingsFile validations initiated in H1H2 FY2023
Vizag supplies to less regulated marketsCertain product supplies beginQ3 FY2023

Key Metrics

MetricQ2 FY23
Revenue₹342 cr, >85% of historical quarterly run rate
Gross margin44.2%, improved 270 bps over Q1; H1 gross margin ~42%
Operating EBITDA₹52.6 cr, 15% margin
Regulated market revenue share66%, sequentially similar
CRAMS revenue share~5% of total revenues
Overall capacity utilization~75%
Net debt to EBITDA (FY23 target)~5x by end of FY23
Net debt to EBITDA (FY24 target)2.5x to 3x by end of FY24
Term debt₹346 cr
Working capital debt₹600 cr
Debt reduction in H1₹12 cr reduced
Expected annual debt repayment~₹100 cr from internal accruals
New market extensions filed (Q2)8 extensions for 9 existing APIs
New market extensions filed (H1)9 extensions for 10 existing APIs
New R&D programs added (FY23)15+ programs
New product filings target (FY23)6 products on track
Pending US FDA approvals (Cuddalore)12 total, including 1 polymer product filed by customer
Brazil filings2 total, target 3-4 in FY23
Historical quarterly revenue run rate₹400 cr minimum, expected return by Q4 FY23
Gross margin target (Q4 FY23)Closer to 50%
Vizag under-recovery offset targetQ4 FY23
Vizag full capacity utilization targetEnd of FY24